Myomo (MYO): Direct-billing prosthetics with concentrated product exposure and expanding payer access

Myomo designs and sells the MyoPro myoelectric orthosis, monetizing primarily through device sales to patients (direct billing to insurers) and wholesale sales to orthotics & prosthetics (O&P) providers; direct billing accounted for 78% of product revenue in 2024 and the Motion G device drove 98% of product revenue, concentrating both revenue and clinical value into a single product family. For investors, the commercial case is straightforward: expand payer network access and scale the direct-billing channel to convert a measurable backlog (roughly $13.6 million maximum potential revenue at year-end 2024) into recurring unit sales while managing warranty, reimbursement timing and O&P channel adoption. If you want a closer look at the company-level evidence and customer map, visit https://nullexposure.com/ for our broader analysis and tools.

How Myomo makes money — concentrated product sales and insurance-driven cashflow

Myomo's economics are driven by device unit sales and insurance reimbursement timing rather than recurring consumables. Revenue recognition for Medicare Part B is governed by CMS published fees and occurs on delivery, creating a near-term cash conversion event when payer documentation is complete. The company sells direct to patients and through O&P providers; when an O&P provider handles fitting and delivery the device is sold at wholesale to that provider, who then bills for clinical services. The business runs with a warranty profile (three-year standard) that adds a multi-year product support obligation, and management has signaled an active investment posture to grow direct billing and O&P revenue in 2025.

• Key commercial levers: payer network expansion, conversion of backlog (~$13.6M potential), O&P channel adoption, and managing warranty/service costs.
• Visit https://nullexposure.com/ to see how these customer dynamics map to cash-flow scenarios and exposure metrics.

The customer map — who pays, partners and competitors

Below I summarize every customer / counterparty relationship surfaced in filings and news, with the primary source noted.

• Centers for Medicare & Medicaid Services (CMS) — According to Myomo’s 2024 Form 10‑K, revenue from Medicare Part B patients is recognized upon delivery and is priced based on CMS published fees, anchoring a material portion of the company’s direct-billing economics to federal reimbursement rules. (Company 2024 10‑K)

• Jiangxi Myomo Medical Assistive Appliance Co., Ltd. — Myomo disclosed a joint‑venture commitment in its 2024 10‑K that the JV will purchase a minimum of $10.75 million of MyoPro control units over the next ten years, providing a multi‑year purchase floor in APAC markets. (Company 2024 10‑K)

• Elevance Health (ELV) — A March 2026 industry note reported that Elevance Health signed new network participation agreements with Myomo, broadening commercial coverage among a large national managed‑care network and improving access for patients with those plans. (Sahm Capital, March 12, 2026)

• Easterseals DuPage & Fox Valley — In a 2018 press item Myomo described a partnership with Easterseals DuPage & Fox Valley to facilitate MyoPro fittings and delivery for adolescent patients, signaling targeted clinical partnerships for pediatric access. (BioSpace, 2018)

• Centers for Medicare & Medicaid Services (CMS) — Earlier reporting in 2020 noted Myomo’s inclusion in the Medicare Supplier Directory, enabling direct billing to Medicare in 39 states plus Washington, D.C., which materially expanded the company’s addressable Medicare footprint. (MassDevice, 2020)

• DME MAC (Medicare billing contractor) — After medical documentation review a Medicare billing contractor (DME MAC) approved and paid two MyoPro claims, demonstrating that adjudication and contractor-level approvals can produce on‑record reimbursements. (MassDevice, 2023)

• Blue Cross/Blue Shield and Commercial Payers — Myomo management has stated that reimbursement for the MyoPro is approved on a case‑by‑case basis by many Medicare Advantage plans, state Blue Cross/Blue Shield plans, certain Medicaid and commercial insurers, and the Veterans Administration, reflecting diverse but negotiated reimbursement pathways. (MassDevice, 2020)

• HNGR (Hanger; inferred ticker HNGR) — Earnings-call coverage from Q3 2025 recorded management commentary that there is substantial interest among Hanger clinicians nationwide in MyoPro devices, indicating potential channel pickup among a major prosthetics/orthotics network. (InsiderMonkey, Q3 2025 earnings call transcript)

• Hanger — The company separately referenced Hanger by name in the same Q3 2025 call transcript, underscoring clinician interest and potential reseller engagement with Myomo’s product line. (InsiderMonkey, Q3 2025 earnings call transcript)

• Ottobock — Management referenced Ottobock as a competitor with an installed clinician base, placing Myomo in a market with established multinational device suppliers. (InsiderMonkey, Q3 2025 earnings call transcript)

• Equal — Myomo’s management cited Equal as another competitor with roughly 90 clinics, illustrating competitive clinic networks driving patient access and fitting capacity. (InsiderMonkey, Q3 2025 earnings call transcript)

What the constraints and disclosures imply about commercial risk

Translate the company’s constraint signals into investor priorities:

• Contracting posture: Myomo is exposed to a mix of spot and longer-term selling dynamics—CMS’s 2023 reimbursement rule change enables lump‑sum sale treatment for Medicare Part B (supporting spot‑sale recognition on delivery), while product warranties and a JV commitment introduce multi‑year obligations and purchase visibility. (Company 10‑K; CMS rule cited in 10‑K)

• Concentration and criticality: Direct billing is both material and critical—78% of 2024 product revenue came from direct billing and the Motion G product accounted for 98% of product revenue—creating single‑product and single‑channel concentration that magnifies execution risk on reimbursement and delivery cadence. (Company 2024 10‑K)

• Counterparty mix and channel maturity: Revenue is derived primarily from individual patients billed through insurers, with meaningful government exposure via the VA network (over 130 VA facilities ordered devices), indicating a blended counterparty base that combines retail patient demand with institutional purchasing. (Company 2024 10‑K)

• Geographic diversification: Myomo sells in North America, Europe/EMEA and APAC (including Canada, Germany, Australia and O&P agreements across several European markets), so scaling internationally is possible but early-stage relative to U.S. direct-billing volumes. (Company 2024 10‑K)

• Stage and runway: The company describes an active ramping posture—investments to grow direct billing and O&P channels in 2025—so investors should expect continued operating deficits while sales capacity expands. Backlog (272 units with ~$13.6M of potential revenue) provides a short‑term revenue runway if authorizations convert. (Company 2024 10‑K)

Investment implications — where upside and risk concentrate

• Upside drivers: expanded payer network agreements (e.g., Elevance), successful conversion of insurance‑authorized backlog, and adoption by O&P networks (Hanger interest) will materially improve unit sales and cash flow timing.
• Key risks: product and channel concentration, adjudication risk at Medicare contractors and commercial payers, and warranty/service costs across a three‑year coverage window.
• Operational focus for management: accelerate payer contracting, deploy clinician training in O&P channels, and convert backlog into deliveries while containing warranty expense.

For investors building exposure models or tracking commercial milestones, Myomo’s path to profitability is straightforward conceptually—scale units and compress the time from insurance authorization to device delivery—but execution hinges on payer relationships and channel adoption. To analyze comparable exposure and build event-driven scenarios, visit https://nullexposure.com/ for detailed monitoring and model inputs.

Bold takeaways: Myomo is a direct‑billing medical‑robotics vendor with concentrated product revenue and expanding payer access; execution on payer contracts and O&P adoption will determine the valuation gap between current revenue and potential scale.